Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

1. Alnylam posted $773.69 million quarterly sales, exceeding expectations by 21%. 2. Amvuttra's launch for ATTR-CM is progressing exceptionally well since FDA approval. 3. Analysts raised Alnylam's 2025 sales forecast to $3.3-$3.55 billion, above consensus. 4. Positive analyst outlooks indicate strong market positioning and growth potential. 5. ALNY stock rose by 1.56% to $398.36, reflecting positive market sentiment.